In an M&A deal, which IP representation best reflects typical validity and enforceability?

In an M&A deal, which IP representation best reflects typical validity and enforceability?

• A. The IP rights are owned by the seller and enforceable, with no known invalid or misappropriated claims.
• B. There are no pending patent applications related to the IP.
• C. All IP infringement insurance is in place.
• D. There are no undisclosed third-party rights that would impair transfer.

Answer: (D)

The main idea here is ensuring a clean title and ability to transfer and enforce the IP without hidden twists. The best representation is that there are no undisclosed third-party rights that would impair transfer. Why this matters: even if the seller owns the IP, third-party rights—such as licenses, co-ownership, liens, or claims by others—can limit how the IP is used, licensed, or enforced after closing. If such rights exist but aren’t disclosed, the buyer could face unexpected royalties, restricted fields of use, or ongoing disputes that undermine value and operability of the IP post-close. By asserting there are no undisclosed third-party rights that would impair transfer, the seller provides the most direct shield against those transferability and enforceability risks. In contrast, statements about no pending patent applications don’t speak to current ownership or enforceability, and guaranteeing no invalid or misappropriated claims can be unrealistic and hard to verify. Relying on an IP infringement insurance policy addresses risk transfer rather than ensuring a clean transfer of rights.

The main idea here is ensuring a clean title and ability to transfer and enforce the IP without hidden twists. The best representation is that there are no undisclosed third-party rights that would impair transfer. Why this matters: even if the seller owns the IP, third-party rights—such as licenses, co-ownership, liens, or claims by others—can limit how the IP is used, licensed, or enforced after closing. If such rights exist but aren’t disclosed, the buyer could face unexpected royalties, restricted fields of use, or ongoing disputes that undermine value and operability of the IP post-close. By asserting there are no undisclosed third-party rights that would impair transfer, the seller provides the most direct shield against those transferability and enforceability risks.

In contrast, statements about no pending patent applications don’t speak to current ownership or enforceability, and guaranteeing no invalid or misappropriated claims can be unrealistic and hard to verify. Relying on an IP infringement insurance policy addresses risk transfer rather than ensuring a clean transfer of rights.